Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatiquinone in Friedreich Ataxia
NCT05515536Phase 3Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of vatiquinone in Friedreich ataxia (FA), sponsored by PTC Therapeutics, Inc.. Started Dec 2022; status: active, not recruiting.
02
Drugs
vatiquinone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT05515536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515536.